Shanghai Senhui Medicine

Senhui Pharmaceutical is a clinical-stage biotechnology company based in Shanghai, China, focused on the discovery and development of innovative small molecule therapeutics. The company primarily targets oncology and metabolic diseases, utilizing a proprietary drug discovery platform to develop best-in-class and first-in-class medicines. Its lead candidate, SH-1573, is an oral selective estrogen receptor degrader (SERD) currently in clinical trials for the treatment of ER-positive, HER2-negative breast cancer. Senhui's pipeline also includes SH-1028, a third-generation EGFR inhibitor targeting lung cancer mutations. The company is backed by prominent venture capital firms like HighLight Capital and maintains research and development facilities in the Zhangjiang Hi-Tech Park. Senhui aims to address significant unmet medical needs through precision medicine and efficient drug development processes.